Panolos Bioscience is a frontrunner in structure-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapies targeting cancer, autoimmune, and rare diseases. Our proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" features a VEGF receptor backbone, enabling the creation of mono- or multi-specific antibody therapeutics with enhanced efficacy.
Starting October 2023, PB101 using αART technology is enrolling for Phase I which is manufactured by Samsung Biologics based on a CDMO partnership. Panolos attracted a development partnership with Kelun-Biotech for PB203 (aka, PKB01), and formed the strategic alliance and CDMO partnership with Chime Biologics for the same. Panolos is developing various pipelines targeting PD-L1, EGFR, and TGF-beta(b)
To support our ongoing development, Panolos Bioscience raised $18 million in Series A funding and is currently seeking a Series B Bridge investment of $20 million in 2023.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 21-Gil 10, Dongtan-Daero, Suite #217,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.panolos.com
- HQ
- Hwaseong-si, Gyeonggi-do
Panolos Bioscience Questions
Panolos Bioscience's website is https://www.panolos.com
Panolos Bioscience's LinkedIn profile is https://kr.linkedin.com/company/panolos-bioscience
Panolos Bioscience has
7 employees.
View email and phone details for 7
employees at Panolos Bioscience.
Panolos Bioscience's industry is
Biotechnology Research
Panolos Bioscience's top competitors are
Connext,
Cmg Pharmaceutical,
Spark Biopharma, Inc.,
Sam Chun Dang Pharm. Co. Ltd,
Nbs Scientific Nl,
Amtixbio,
Wooshin Lapache,
Metimedi Co., Ltd.,
Gi Cell (지아이셀),
Poolbeg Pharmaceuticals.
Panolos Bioscience's categories are Biotechnology Research
Panolos Bioscience's founding year is 2019
